emeis Société anonyme

ENXTPA:EMEIS Stock Report

Market Cap: €771.7m

emeis Société anonyme Valuation

Is EMEIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EMEIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EMEIS (€4.79) is trading below our estimate of fair value (€85.24)

Significantly Below Fair Value: EMEIS is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for EMEIS?

Key metric: As EMEIS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EMEIS. This is calculated by dividing EMEIS's market cap by their current earnings.
What is EMEIS's PE Ratio?
PE Ratio0.5x
Earnings€1.47b
Market Cap€771.73m

Price to Earnings Ratio vs Peers

How does EMEIS's PE Ratio compare to its peers?

The above table shows the PE ratio for EMEIS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14.8x
LNA LNA Santé
9.9x7.4%€235.7m
EQS Equasens Société anonyme
15.8x11.4%€665.9m
BLC Bastide Le Confort Médical
23.9x33.5%€176.5m
GBT Guerbet
9.6x18.3%€315.2m
EMEIS emeis Société anonyme
0.5x-108.0%€771.7m

Price-To-Earnings vs Peers: EMEIS is good value based on its Price-To-Earnings Ratio (0.5x) compared to the peer average (14.8x).


Price to Earnings Ratio vs Industry

How does EMEIS's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.18.4x24.4%
EMEIS emeis Société anonyme
0.5x-108.0%US$810.55m
EMEIS 0.5xIndustry Avg. 18.4xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
Industry Avg.18.4x24.4%
EMEIS emeis Société anonyme
0.5x-108.0%US$810.55m
No more companies

Price-To-Earnings vs Industry: EMEIS is good value based on its Price-To-Earnings Ratio (0.5x) compared to the European Healthcare industry average (18.5x).


Price to Earnings Ratio vs Fair Ratio

What is EMEIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EMEIS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.5x
Fair PE Ratio2x

Price-To-Earnings vs Fair Ratio: EMEIS is good value based on its Price-To-Earnings Ratio (0.5x) compared to the estimated Fair Price-To-Earnings Ratio (2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EMEIS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.79
€10.53
+119.5%
28.6%€14.00€7.20n/a4
Dec ’25€5.84
€10.53
+80.1%
28.6%€14.00€7.20n/a4
Nov ’25€6.31
€11.63
+84.5%
23.0%€14.00€7.90n/a3
Oct ’25€5.47
€11,633.33
+212,419.8%
23.0%€14,000.00€7,900.00n/a3
Sep ’25€8.98
€11,633.33
+129,418.3%
23.0%€14,000.00€7,900.00n/a3
Aug ’25€10.29
€11,633.33
+112,976.7%
23.0%€14,000.00€7,900.00n/a3
Jul ’25€12.31
€11,725.00
+95,132.3%
24.7%€15,000.00€7,900.00n/a4
Jun ’25€12.94
€11,725.00
+90,510.5%
24.7%€15,000.00€7,900.00n/a4
May ’25€12.80
€10,975.00
+85,642.2%
20.7%€14,000.00€7,900.00n/a4
Apr ’25€10.14
€6,230.00
+61,352.0%
95.5%€14,000.00€20.00n/a4
Mar ’25€12.60
€3,640.00
+28,788.9%
123.9%€10,000.00€20.00n/a3
Feb ’25€13.50
€2,737.50
+20,177.8%
153.7%€10,000.00€20.00n/a4
Jan ’25€16.90
€2,737.50
+16,098.2%
153.7%€10,000.00€20.00n/a4
Dec ’24€16.40
€2,737.50
+16,592.1%
153.7%€10,000.00€20.00€5.844
Nov ’24€894.99
€3,910.00
+336.9%
117.1%€10,000.00€20.00€6.315
Oct ’24€1,424.50
€3,909.99
+174.5%
117.1%€10,000.00€20.00€5.475
Sep ’24€1,672.50
€3,909.99
+133.8%
117.1%€10,000.00€20.00€8.985
Aug ’24€1,740.49
€3,939.99
+126.4%
115.6%€10,000.00€30.02€10.295
Jul ’24€1,889.49
€4,005.97
+112.0%
112.3%€10,000.00€170.01€12.315
Jun ’24€1,849.99
€4,917.48
+165.8%
93.5%€10,000.00€170.01€12.944
May ’24€2,676.00
€5,561.99
+107.8%
76.7%€10,000.00€289.94€12.805
Apr ’24€1,966.99
€5,601.65
+184.8%
69.5%€10,000.00€289.94€10.146
Mar ’24€2,476.00
€10,944.27
+342.0%
124.0%€43,000.00€289.94€12.607
Feb ’24€5,539.99
€13,688.58
+147.1%
91.1%€43,000.00€4,000.00€13.507
Jan ’24€6,171.99
€17,165.00
+178.1%
86.5%€43,000.00€4,000.00€16.908
Dec ’23€6,694.00
€17,415.00
+160.2%
84.1%€43,000.00€5,799.97€16.408

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 15:40
End of Day Share Price 2024/12/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

emeis Société anonyme is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lionel PellicerAlphaValue
Stéphan DubosqArkeon Finance
Beatrice AllenBerenberg